It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases

News Releases

2020
March
Pharmaceuticals
Development of the first comprehensive genomic profiling assay for hematologic malignancies in Japan- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evaluate its clinical utility -
Pharmaceuticals
Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)
Pharmaceuticals
Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Pharmaceuticals
Cabpirin® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin
Nutraceuticals
Dietary Education App "SketchCook"
Recognized with Ministry of Education, Culture, Sports, Science and Technology(MEXT)
"Award for Companies Promoting Experience-based Learning Activities for Youth 2019"
Nutraceuticals
Newly published findings on inhibitory effect of near-infrared (IRA) radiation on human epidermal cell proliferation and potential mechanisms
Corporate
Otsuka Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors (PDF:57.4 KB)
Nutraceuticals
Introducing InnerSignal Rejuvenate ONE-All-in-One Skin Care Product with Time-Lapse Penetration Combines Lightening and Three Basic Skin Care Functions-
Pharmaceuticals
Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan
2019